Last reviewed · How we verify
Azidamphenicol — Competitive Intelligence Brief
phase 2
azidamfenicol
Infectious Disease
Small molecule
Live · refreshed every 30 min
Target snapshot
Azidamphenicol (AZIDAMFENICOL). Azidamfenicol works by binding to the 50S ribosomal subunit of bacteria, preventing the formation of peptide bonds and thereby inhibiting protein synthesis.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Azidamphenicol TARGET | AZIDAMFENICOL | phase 2 | azidamfenicol |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (azidamfenicol class)
- · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Azidamphenicol CI watch — RSS
- Azidamphenicol CI watch — Atom
- Azidamphenicol CI watch — JSON
- Azidamphenicol alone — RSS
- Whole azidamfenicol class — RSS
Cite this brief
Drug Landscape (2026). Azidamphenicol — Competitive Intelligence Brief. https://druglandscape.com/ci/azidamfenicol. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing